Chargement en cours...
Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience
BACKGROUND: Metastatic uveal melanoma (MUM) is associated with a poor prognosis, with a median overall survival (OS) of 4–15 months. Despite new insights into the genetic and molecular background of MUM, satisfactory systemic treatment approaches are currently lacking. The study results of innovativ...
Enregistré dans:
| Publié dans: | Case Rep Oncol Med |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Hindawi
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6501230/ https://ncbi.nlm.nih.gov/pubmed/31179139 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/3560640 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|